SCHEMBL14320775

SCHEMBL14320775

Nc1cccc(Nc2nc(-c3ccsc3)nc3cn[nH]c23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSC P53634 2/20 0.46
JAK2 O60674 3/20 0.42
MAPKAPK2 P49137 1/20 0.41
ABCG2 Q9UNQ0 5/20 0.39
SYK P43405 2/20 0.38
ROCK2 O75116 2/20 0.38
MAP3K5 Q99683 1/20 0.36
LATS1 O95835 1/20 0.36
GBA1 P04062 1/20 0.36
CTSL P07711 1/20 0.35
EGFR P00533 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
ABL1 P00519 1/20 0.34
BCR P11274 1/20 0.34
SRC P12931 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320313 0.88 ABCG2 (0.48) JAK2ABCG2SYKGBA1
SCHEMBL14320830 0.85 ABCG2 (0.48) JAK2MAPKAPK2ABCG2SYKLATS1
SCHEMBL14320986 0.83 JAK2 (0.44) JAK2MAPKAPK2SYKROCK2ALDH1A1
SCHEMBL14320351 0.80 ABCG2 (0.49) JAK2ABCG2
SCHEMBL27932672 0.79 JAK2 (0.49) JAK2MAPKAPK2ABCG2SYKROCK2
SCHEMBL17135653 0.78 JAK2 (0.49) CTSCJAK2MAPKAPK2SYKGBA1
SCHEMBL14320643 0.78 JAK2 (0.49) JAK2SYKLMNAHPGD
SCHEMBL14321007 0.78 JAK2 (0.47) CTSCJAK2MAPKAPK2ABCG2SYK
SCHEMBL14320876 0.78 KDR (0.47) JAK2SYKROCK2LATS1
SCHEMBL13736972 0.76 JAK2 (0.45) JAK2MAPKAPK2ABCG2SYKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK CTSC 2042/4885JAK2 60/4885MAPKAPK2 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.